The R&D investments in the quarter ramped up to ~7.6 per cent of revenues
Cipla Limited announced its audited consolidated financial results for the full year and quarter ended March 31, 2018. The company reported full year revenues of Rs 15,219 crores, growing six per cent # year on year (y-o-y).
EBITDA margins, before exceptional items, increased by over 160bps to 18.6 per cent. For the quarter ended March 31, the company reported revenues of Rs 3,698 crores, growing five per cent # y-o-y. The R&D investments in the quarter ramped up to ~7.6 per cent of revenues.
The company continues its growth momentum across key markets with India business delivering a strong quarter with growth at 21 per cent (GST adjusted) y-o-y. South Africa, API, Europe and sub Saharan markets. The US business saw launches of key products.
“This financial year, our focus remained on strengthening our portfolio and deepening our presence in priority markets. We are happy that our efforts on cost and efficiency improvement helped us deliver the full year margin ahead of our guidance range. Our focus for next year will be to continue our growth trajectory in key markets and investments in portfolio for sustainable growth. We continue to strive to make a difference to patients through meeting unmet needs and our continuing focus on quality and innovation” said, Umang Vohra, Managing Director and Global CEO, Cipla.
* Without the impact of exceptional items in Q4FY18; % of revenues
# Adjusted for GST impact
^ % of revenues